亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

160P COLUMBIA-1: A phase Ib/II, open-label, randomized, multicenter study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab as first-line (1L) therapy in metastatic microsatellite-stable colorectal cancer (MSS-mCRC)

医学 贝伐单抗 内科学 临床终点 不利影响 穿孔 福克斯 肿瘤科 奥沙利铂 化疗 胃肠病学 结直肠癌 外科 随机对照试验 癌症 冶金 冲孔 材料科学
作者
Neil H. Segal,J. Tie,S. Kopetz,M.P. Ducreux,E. Chen,R. Dienstmann,A. Hollebecque,M. Reilley,M.E. Elez Fernandez,J. Cosaert,Joan E. Cain,M. Hernandez,N. Hewson,Z.A. Cooper,M. Dressman,J. Tabernero
出处
期刊:Immuno-oncology technology [Elsevier BV]
卷期号:16: 100272-100272 被引量:3
标识
DOI:10.1016/j.iotech.2022.100272
摘要

Despite advances in the treatment of mCRC combining chemotherapy regimens with biologics, most patients (pts) still progress within 11 months of receiving 1L chemotherapy. Addition of novel therapies to the standard of care (SoC) to improve antitumor activity is urgently needed. The randomized part 2 of COLUMBIA-1 (NCT04068610) evaluated the safety and efficacy of combining SoC (bevacizumab [BEV] + FOLFOX) with the PD-L1 inhibitor durvalumab (D) and the anti-CD73 monoclonal antibody oleclumab (O). Pts with previously untreated, MSS-mCRC and ECOG PS ≤1 received either SoC alone or SoC + D (1500 mg, Q4W) + O (3000 mg Q2W x4 then Q4W) in the experimental arm (EXP). The primary endpoint was objective response rate (ORR) per investigator assessed RECIST v1.1. As of 10 Dec 2021, 52 pts were enrolled, of whom 51 were response evaluable. The confirmed ORR with SoC was 44.0% (95% confidence interval [CI], 24.4–65.1%) compared to 61.5% (95% CI, 40.6–79.8%) in the EXP arm. Median OS was not reached (SoC) vs 19.1 mos (EXP); median PFS was 11.1 mos (SoC) vs 10.9 mos (EXP; Table). Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 76.9% of pts in SoC and 65.4% EXP. Fatal TEAEs (all unrelated) were observed in 3 pts in the EXP arm: 1 with sepsis and 2 with intestinal perforation. One pt with intestinal perforation deemed related to BEV experienced fatal peritonitis. In the SoC arm, there was a single fatal COVID-19 TEAE. The most frequent treatment-related AEs in the EXP arm were diarrhea (38.5%), peripheral sensory neuropathy (38.5%) and fatigue (26.9%). There was no identified association between CD73 expression and clinical benefit. Addition of D + O to FOLFOX + BEV SoC showed a moderate response increase without PFS benefit vs SoC alone. Safety was consistent with known safety profiles.Table: 160PRECIST v1.1Response Evaluable PopulationSoC (n=25)EXP (n=26)Best Overall Response, n (%)Confirmed CR01 (3.8)Confirmed PR11 (44.0)15 (57.7)SD12 (48.0)7 (26.9)Unconfirmed PR3 (12.0)1 (3.8)PD1 (4.0)2 (7.7)Unknown/not evaluable1 (4.0)1 (3.8)ORR, n (%) [95% CI %]11 (44) [24.4, 65.1]16 (61.5) [40.6, 79.8]Disease Control, n (%) [95% CI %]23 (92.0) [74.0, 99.0]23 (88.5) [69.8, 97.6]Median DoR, mos (95% CI %)7.6 (3.7, NE)10.3 (5.8, 14.9)Median PFS, mos (95% CI %)**11.1 (7.3, 19.3)10.9 (6.9, 15.1)PFS rate at 12 mos, % (95% CI %)**35.9 (16.2, 56.2)36.1 (17.1, 55.5)Median OS, mos (95% CI %)**NR (18.2, NE)19.1 (10.6, NE)*NE=Not Estimable; **ITT Population: SoC (n=26), EXP (n=26) Open table in a new tab

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
ZhaoYX完成签到 ,获得积分10
14秒前
lyw完成签到 ,获得积分10
16秒前
粗心的丹萱完成签到,获得积分10
18秒前
22秒前
22秒前
MchemG的应助被科研通管家采纳,获得30
22秒前
25秒前
平常以云完成签到 ,获得积分10
27秒前
打打的应助被渟柠采纳,获得10
41秒前
高挑的天问完成签到,获得积分10
47秒前
49秒前
渟柠发布了新的文献求助10
52秒前
FashionBoy的应助被yyzc6162采纳,获得10
57秒前
1分钟前
1分钟前
慕青的应助被amiee采纳,获得10
1分钟前
自由的小熊猫完成签到,获得积分10
1分钟前
DDL完成签到 ,获得积分10
1分钟前
1分钟前
Orange的应助被小梁采纳,获得10
1分钟前
amiee发布了新的文献求助10
1分钟前
1分钟前
小梁发布了新的文献求助10
1分钟前
丰富含桃完成签到,获得积分10
1分钟前
Negiiii完成签到,获得积分10
2分钟前
Shicheng完成签到,获得积分10
2分钟前
MchemG的应助被科研通管家采纳,获得30
2分钟前
CodeCraft的应助被科研通管家采纳,获得10
2分钟前
忧郁的涵雁完成签到 ,获得积分10
2分钟前
3分钟前
3分钟前
lingrong发布了新的文献求助10
3分钟前
M.发布了新的文献求助10
3分钟前
M.完成签到,获得积分10
3分钟前
3分钟前
酷波er的应助被lingrong采纳,获得10
3分钟前
佳言2009完成签到 ,获得积分10
3分钟前
负责的初柔完成签到 ,获得积分10
4分钟前
科研通AI6.4的应助被张阳采纳,获得10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190136
求助须知:如何正确求助?哪些是违规求助? 9577239
关于积分的说明 21852194
捐赠科研通 7788466
什么是DOI,文献DOI怎么找? 3436259
关于科研通互助平台的介绍 2560043
邀请新用户注册赠送积分活动 2482880